Your browser doesn't support javascript.
loading
Assessing the Safety and Efficacy of Two Starting Doses of Lenvatinib Plus Everolimus in Patients with Renal Cell Carcinoma: A Randomized Phase 2 Trial.
Pal, Sumanta K; Puente, Javier; Heng, Daniel Y C; Glen, Hilary; Koralewski, Piotr; Stroyakovskiy, Daniil; Alekseev, Boris; Parnis, Francis; Castellano, Daniel; Ciuleanu, Tudor; Lee, Jae Lyun; Sunela, Kaisa; O'Hara, Karen; Binder, Terri A; Peng, Lixian; Smith, Alan D; Rha, Sun Young.
Afiliación
  • Pal SK; Department of Medical Oncology & Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA. Electronic address: spal@coh.org.
  • Puente J; Medical Oncology Department, Hospital Clinico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), CIBERONC, Madrid, Spain.
  • Heng DYC; Department of Oncology, Tom Baker Cancer Center, Calgary, Alberta, Canada.
  • Glen H; Medical Oncology, Beatson West of Scotland Cancer Centre, Glasgow, UK.
  • Koralewski P; Department of Oncology, Rydygier Hospital, Krakow, Poland.
  • Stroyakovskiy D; Chemotherapeutic Department, Moscow City Oncology Hospital, Moscow, Russian Federation.
  • Alekseev B; Moscow Hertzen Oncology Institute, Moscow, Russian Federation (Alekseev).
  • Parnis F; Medical Oncology, Adelaide Cancer Center, Adelaide, Australia.
  • Castellano D; Medical Oncology Department, Hospital Universitario 12 de Octubre (CIBERONC), Madrid, Spain.
  • Ciuleanu T; Medical Oncology, Iuliu Hatieganu University of Medicine and Pharmacy, Ion Chiricuta Institute of Oncology, Cluj-Napoca, Romania.
  • Lee JL; Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea.
  • Sunela K; Department of Oncology, Tampere University Hospital, Tampere, Finland.
  • O'Hara K; Eisai Europe Ltd., Hatfield, UK.
  • Binder TA; Eisai Inc., Nutley, NJ, USA.
  • Peng L; Eisai Inc., Nutley, NJ, USA.
  • Smith AD; Eisai Europe Ltd., Hatfield, UK.
  • Rha SY; Department of Medical Oncology, Yonsei Cancer Center, Yonsei University Health System, Seoul, South Korea. Electronic address: rha7655@yuhs.ac.
Eur Urol ; 82(3): 283-292, 2022 09.
Article en En | MEDLINE | ID: mdl-35210132
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Carcinoma de Células Renales / Neoplasias Renales Tipo de estudio: Clinical_trials Límite: Humans Idioma: En Revista: Eur Urol Año: 2022 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Carcinoma de Células Renales / Neoplasias Renales Tipo de estudio: Clinical_trials Límite: Humans Idioma: En Revista: Eur Urol Año: 2022 Tipo del documento: Article